Shock, Septic Clinical Trial
— OFTaPLROfficial title:
Optimization of Fluid Therapy by a Passive Leg Raising Test in Patients With Septic Shock in the ICU
Verified date | February 2016 |
Source | Karolinska Institutet |
Contact | n/a |
Is FDA regulated | No |
Health authority | Sweden: Regional Ethical Review Board |
Study type | Interventional |
A randomized controlled clinical trial to evaluate whether a passive leg raising test to
guide fluid therapy of patients with septic shock can reduce fluid balance and weight gain.
Patients will be treated according to an algorithm in which the indexed stroke volume
(stroke volume related to body surface area) and mean arterial pressure will guide the
timing and amount of fluid and the use of inotropic and vasoactive support. Patients will be
randomized to either an intervention group in which a passive leg raising test will be made
prior to any decision for fluid administration or to a control group where this test is not
performed and fluid administration is carried out according to standard of care at the
department.
Hypothesis: A passive leg raising test, will reduce weight gain by day 3 by 30%.
Status | Terminated |
Enrollment | 34 |
Est. completion date | February 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: All patients >18 years admitted to the ICU diagnosed with circulatory shock due to suspected sepsis or pancreatitis. Circulatory shock is defined as MAP<70 mm Hg or need for norepinephrine despite resuscitation with =30 ml/kg of crystalloid fluids. Exclusion Criteria: > 12 hours have passed after onset of shock. The patient has contraindications for an arterial femoral/axillary line. Elevated ICP. Patients who have had a femoral amputation. Elevated intraabdominal pressure>20 cm H2O. Suspension criteria: The patient has developed pulmonary oedema during PLR test. Life threatening bleeding. Serious adverse events: Trombosis in arteria femoralis. Death during the study period. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Sweden | Karolinska Institutet Södersjukhuset | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Karolinska Institutet | Stockholm County Council, Sweden, Svenska militärläkarföreningen |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | weight gain | 3 days | No | |
Secondary | ICU length of stay | Number of days spent in the ICU: time and date of discharge from the ICU minus time and date of admission to the ICU. A started but not yet completed day is counted as one. | measured within 90 days after inclusion | No |
Secondary | Cumulative fluid balance study day 1,2,3 | Fluids in-Fluids out during the study period. | Study day 1,2,3 | No |
Secondary | 30 day mortality | Is the patient alive or dead after 30 days? | 30 days from inclusion in the study | No |
Secondary | Organ support during ICU stay | Number of days with mechanical ventilation, vasopressors/inotropic support, CRRT. | ICU-stay | No |
Secondary | ICU discharge status | Alive or dead at discharge from the ICU? | End of ICU stay | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03592693 -
Vitamin C, Hydrocortisone and Thiamine for Septic Shock
|
Phase 2 | |
Terminated |
NCT01639664 -
COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2
|
N/A | |
Withdrawn |
NCT01601938 -
Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients
|
Phase 2 | |
Recruiting |
NCT00335907 -
Protocol-driven Hemodynamic Support for Patients With Septic Shock
|
N/A | |
Completed |
NCT00000574 -
Ibuprofen in Sepsis Study
|
Phase 3 | |
Recruiting |
NCT04910841 -
Feasibility of Using the "CGM GUARDIAN 2" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine
|
N/A | |
Active, not recruiting |
NCT04079829 -
Postoperative Respiratory Abnormalities
|
||
Recruiting |
NCT04569942 -
Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis
|
Phase 3 | |
Recruiting |
NCT04934943 -
"Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools"
|
||
Completed |
NCT01310790 -
Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock
|
Phase 4 | |
Completed |
NCT00241228 -
Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care)
|
N/A | |
Completed |
NCT00046072 -
A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis
|
Phase 2 | |
Withdrawn |
NCT03122678 -
Thiamine Supplementation in Patients With Septic Shock
|
Phase 1 | |
Recruiting |
NCT06155812 -
Multimodal Vasopressor Strategy in Septic Shock
|
Phase 2/Phase 3 | |
Completed |
NCT04178148 -
Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock
|
N/A | |
Completed |
NCT01453270 -
Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial
|
N/A | |
Completed |
NCT04576819 -
Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis
|
||
Active, not recruiting |
NCT04055909 -
Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock
|
Phase 2 | |
Suspended |
NCT03193164 -
Neuromuscular Electrical Stimulation and Septic Shock
|
N/A | |
Completed |
NCT04647552 -
Effects of Hydrocortison Treatment on Angiotensin II and Angiotensin II Receptors in Patients With Septic Shock
|